Erfahrungen mit der digitalen Versorgung von Patienten mit chronischen und akuten Lungenerkrankungen während der SARS-CoV-2-Pandemie

Braun, Marcel; Schmidt, Olaf; Schultz, Thomas; Woehrle, Holger; Sundrup, Martina Große; Schöbel, Christoph

doi:10.1007/s00108-022-01266-3

Cited by 9 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bereits 2019 waren mehr als 500 Asthma-bezogene Gesundheits-Apps verfügbar 524 . Durch die COVID-19-Pandemie ist seit 2020 ein weiterer Entwicklungssprung eingetreten 525 . Der überwiegende Anteil der Literatur zu digitalen Unterstützungs-Systemen bei Patienten mit Asthma zieht ein positives Fazit zu den Einsatzmöglichkeiten von telemedizinischen Anwendungen, insbesondere zur Verbesserung der Adhärenz und zum verbesserten Monitoring der Patienten mit Asthma 195 523 526 527 528 529 530 531 532 533 534 .…”

Section: Digitale Unterstützungssysteme In Der Diagnostik Und Therapi...unclassified

S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023

et al. 2023

Self Cite

View full text Add to dashboard Cite

ZusammenfassungDas Management von Asthma hat sich in den letzten Jahrzehnten fundamental gewandelt. Die vorliegende Leitlinie zur Diagnostik und Therapie von Asthma wurde für pneumologisch tätige Fachärztinnen und Fachärzte entwickelt, welche detaillierte und evidenzbasierte Informationen zu den neuen diagnostischen und therapeutischen Optionen von Asthma benötigen. Die Leitlinie zeigt die neue Bedeutung der Biomarker, insbesondere der Bluteosinophilen und des exhalierten NO (FeNO), in den diagnostischen Algorithmen von Asthma. Als erste Asthma-Leitlinie weltweit benennt die vorliegende Leitlinie die nachhaltige Symptomprävention und die Asthma-Remission als Asthma-Therapieziele, welche durch den Einsatz individuell angepasster, krankheitsmodifizierender Medikamente (wie inhalative Steroide, Allergenimmuntherapie oder Biologika) erreicht werden können. Die zentrale Bedeutung der Behandlung von typischen Asthma-Komorbiditäten wird zudem betont. Schließlich wird auch auf besondere Herausforderungen im Asthma-Management eingegangen, wie bspw. die Therapie von Asthma in der Schwangerschaft, die Behandlung von schwerem Asthma oder die Diagnostik und Therapie von arbeitsbedingten Asthma-Formen.

show abstract

Section: Digitale Unterstützungssysteme In Der Diagnostik Und Therapi...unclassified

S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…• System Usability Scale (SUS) [23] • Remote monitoring evaluation questionnaire (RMEQ): this questionnaire was adapted from Braun et al [24] and specifically tailored to the MyaLink platform • Dropout rate Data from external devices (activity tracker, digital spirometer):…”

Section: Secondary Outcome Measuresmentioning

confidence: 99%

The telemedical platform MyaLink for remote monitoring in myasthenia gravis: Rationale and protocol for a proof of concept study

Stein,

Meisel,

Moench

et al. 2024

Preprint

View full text Add to dashboard Cite

Rationale: Myasthenia gravis (MG) is a rare, chronic neurological disorder leading to fluctuating muscle weakness and potentially life-threatening crises. Patients often require life-long specialized treatment, but timely interventions are frequently hindered by the limited availability of specialists. Telemedical solutions at specialized centers enabling patient-physician interaction hold promise in bridging this gap, but are not yet available for MG. We developed 'MyaLink,' a remote monitoring platform tailored for MG, and outline the study design assessing the platform and clinical outcomes regarding telemedical intervention. Additionally, we present study results on care-related aspects in MG prior to telemedical intervention to identify challenges in the current care provision process. Design: The platform comprises a patient app and a physician portal, enabling systematic symptom monitoring using data from patient-reported outcome measures (PROMs), coupled devices and a communication module. The randomized controlled study included 45 study participants (SP) over a 12-weeks period, including a group receiving standard care (15 MG patients) and a group with additional telemedical treatment (30 MG patients) including assessment of PROMs, wearable data collection and telemedical check-ups. Questions regarding care-related aspects were assessed at baseline visit. Results: Many SP (N=33, 73.3%) communicate with the physician managing their MG via email. 73.3% (N=33) of SP identify areas for improvement in their MG care including symptom monitoring (N=23, 69.7%), specialist appointment availability (N=22, 66.7%), medication (N=22, 66.7%) and specialist accessibility (N=20, 60.6%). Additionally, 73.3% (N=33) reported that the effort required to manage their MG was high. Conclusion: Our results emphasize the high demand of affected MG patients for continuous telemedicine services. MyaLink can provide such a service through personalized support based on the exchange of health data. Telemedicine solutions such as MyaLink promise to improve myasthenia care by providing accessible, patient-centred care that enables early detection of worsening symptoms and non-response to treatment.

show abstract

“…The role of the patient could also be acknowledged and fortified through the use of patient support programs, including medication management and counselling offered by nurses or phone services or provided by online resources, which have been shown to have a positive impact on therapy adherence in chronic diseases [37,38]. During the COVID-19 pandemic, an app-based care program for German patients with chronic and acute lung disease had positive impacts on the patient's quality of life and increased therapy adherence [39]. A potentially valuable objective, a center-specific telephone hotline for better patient support in the context of the NTM-PD therapy was rejected from the list of best practices during this study due to a lack of financial resources.…”

Section: Best Practices During Therapymentioning

confidence: 99%

Best Practices for the Management of Patients with Non-Tuberculous Mycobacterial Pulmonary Disease According to a German Nationwide Analysis of Expert Centers

Rohde,

Eichinger,

Gläser

et al. 2023

Healthcare

View full text Add to dashboard Cite

Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic inflammatory lung disease caused by infection with non-tuberculous mycobacteria (NTM). International guidelines provide evidence-based recommendations on appropriate diagnosis and treatment strategies, but there is a need for sharing day-to-day best practice between treatment centers to optimize patient care. This is particularly valuable for rare diseases like NTM-PD. In this cross-sectional analysis of NTM-PD management in Germany, medical and administrative staff from seven treatment centers were interviewed to identify best practice in the diagnosis, treatment, and ongoing management of patients with NTM-PD, including related hospital infrastructure and administration processes. A prioritization led to a collection of best practices for the management of patients with NTM-PD in Germany, which is presented here. Selected current best practices included performance of regular sputum tests for diagnosis, use of medical reports, and regular follow-up visits as well as increased interaction between physicians across different specialties. Future best practices that may be implemented to overcome current barriers comprised disease awareness activities, patient empowerment, and new approaches to enhance physician interaction. Challenges related to their implementation are also discussed and will help to raise disease awareness. The presented best practices may guide and optimize patient management in other centers.

show abstract

Erfahrungen mit der digitalen Versorgung von Patienten mit chronischen und akuten Lungenerkrankungen während der SARS-CoV-2-Pandemie

Cited by 9 publications

References 22 publications

S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023

S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023

The telemedical platform MyaLink for remote monitoring in myasthenia gravis: Rationale and protocol for a proof of concept study

Best Practices for the Management of Patients with Non-Tuberculous Mycobacterial Pulmonary Disease According to a German Nationwide Analysis of Expert Centers

Contact Info

Product

Resources

About